Who We Are
Elizabeth Reczek, Ph.D. – President and Chief Scientific Officer
Dr. Reczek joined Excelimmune, Inc. in 2007. She was a founding member of the company's original research team, which was responsible for the development of Excelimmune's core human antibody discovery technology, from initial concept through to the successful isolation of antibodies against Staphylococcus aureus from human donors. From 2010 to 2012, as Director of Research, Dr. Reczek oversaw the development of the company's Antibody Combination Therapeutic (ACT) expression technology and is a named inventor on the patent, awarded in December of 2013. In February 2013, Dr. Reczek assumed the role of President and CEO. She currently serves as the company's President and Chief Scientific Officer. Elizabeth obtained her Ph.D. in Cancer Biology at MIT, followed by a post-doctoral fellowship focused on tumor cell signaling pathways at Brigham and Women's Hospital and Harvard Medical School.
Jason M. Walsh, MBA – Chief Financial Officer and Vice President of Corporate Development
Mr. Walsh, a senior finance and operations executive with over twenty years of biotechnology management experience, joined Excelimmune, Inc. in early 2013 to lead finance and corporate development activities. Previously, Jason was a founder and Chief Business Officer of the cancer therapeutic company, Provenance Biopharmaceuticals Corp. At Provenance, he led all finance, business operations, and corporate development activities. He raised several rounds of financing and helped advance the company's lead molecule into the clinic. Prior to starting Provenance, Jason was Head of Finance and Business Operations for Lexigen Pharmaceuticals Corp. There, he helped lead Lexigen from its start-up phase through various stages of funding and multiple corporate pharmaceutical company partnerships and, ultimately, to the successful sale to the global pharmaceutical company, Merck KGaA. Prior to his executive position at Lexigen, Jason founded and led several entrepreneurial ventures in a wide range of industries. He is a founder, Treasurer and member of the Board of Directors of The Bioscience Network, a non-profit educational and professional development organization for the life science industry. He has his Masters in Business Administration from Babson College.
Thomas A. Dahl, PhD – Vice President of Product Development
Dr. Dahl joined Excelimmune, Inc. in 2013 as Vice President of Product Development. Tom has more than 20 years of experience in experimental therapeutics in both academia and biopharmaceutical industry, including product development, clinical trial design, execution and interpretation, as well as experience in data presentation to funding communities, analysts, and biotech and pharmaceutical partners. He has held senior management positions in a number of biotech companies, including CEO, COO and VP of Clinical Development. Additionally, Tom has served as an advisor and consultant to biotech companies, specializing in start-ups and early stage (through Phase 2 clinical trials) development. He has submitted a total of 8 INDs to the FDA across multiple therapeutic areas including infectious diseases, and has designed and overseen more than 30 clinical trials. Tom received his Ph.D. from The Johns Hopkins University and served on the faculty of Tufts Medical, Dental and Veterinary Schools for several years before joining the biotech community.
Hugh H. Russell, PhD – Director of Antibody Technologies
Dr. Russell joined Excelimmune, Inc. in 2007 as a founding member of the company's original research team. During his tenure, Hugh has overseen the development of the antibody discovery and screening platforms, and initiated functional in vitro studies for characterization of anti-S. aureus antibodies. As Director of Antibody Technologies, Hugh works on the pre-clinical development of antibody technologies and on intellectual property for Excelimmune. Hugh received his Ph.D. in Infectious diseases from the Imperial College London using molecular and biochemical methods to study Gram positive bacterial pathogens.
Karoly Nikolich, PhD – Executive Chairman
Dr. Nikolich is an experienced executive in biotechnology and life science companies, and an expert in central nervous system therapeutics with a successful track record in creating and leading early- and late-stage companies and programs. He held senior R&D leadership and executive positions at leading large biotechnology and technology platform companies. Additionally, he founded and served as CEO of three early-stage biotechnology/life science companies. During his 12 years at Genentech, Dr. Nikolich initiated and built the company's first neuroscience program, led and participated in preclinical and clinical development programs, including nerve growth factor, new neurotrophic factors, tPA for stroke, growth hormone and heregulin. As VP of Research at Lynx Therapeutics, he established and managed a major partnership with BASF in Germany and was part of the management team that carried the company's public stock offering. Dr. Nikolich has a strategic perspective and vision to create pioneering, proprietary therapies for CNS diseases. He established and managed many successful partnerships, collaborations, and licenses with companies, as well as, with academic and government institutions. As a scientist, Dr. Nikolich has published over 130 research and review articles, and has served as an investment advisor to several public and private venture funds